0
0

Chapter 40. Topiramate

Susan L. McElroy, M.D.; Paul E. Keck, M.D.
DOI: 10.1176/appi.books.9781585623860.414542

Sections

Excerpt

Topiramate is a derivative of the naturally occurring monosaccharide d-fructose. It was originally synthesized to be a structural analog of fructose-1,6-diphosphatase as part of a project to develop agents that inhibit gluconeogenesis by inhibiting the enzyme fructose-1,6-biphosphatase (Shank et al. 2000). To date, however, it has not been shown by clinical evidence to have direct hypoglycemic activity. Topiramate contains a sulfamate moiety. The structural resemblance of this moiety to the sulfonamide moiety in the established antiepileptic drug acetazolamide prompted researchers to evaluate topiramate for possible anticonvulsant effects. Topiramate subsequently was shown to have potent anticonvulsant properties in a broad range of preclinical epilepsy models (Shank et al. 2000).

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

FIGURE 40–1. Chemical structure of topiramate.

References

Abraham G, Owen J: Topiramate can cause lithium toxicity. J Clin Psychopharmacol 24:565–567, 2004
[PubMed]
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
 
Anthenelli RM, Blom TJ, McElroy SL, et al: Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction 103:687–694, 2008
[PubMed]
 
Astrup A, Caterson I, Zelissen P, et al: Topiramate: long-term maintenance of weight loss induced by low-calorie diet in obese subjects. Obes Res 12:1658–1669, 2004
[PubMed]
 
Bahk WM, Shin YC, Woo J, et al: Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Prog Neuropsychopharmacol Biol Psychiatry 29, 115–121, 2005
 
Barzman DH, DelBello MP: Topiramate for co-occurring bipolar disorder and disruptive behavior disorders (letter). Am J Psychiatry 163:1451–1452, 2006
[PubMed]
 
Bialer M, Doose DR, Murthy B, et al: Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 43:763–780, 2004
[PubMed]
 
Biton V, Edwards KR, Montouris GD, et al: Topiramate titration and tolerability. Ann Pharmacother 35:173–179, 2001
[PubMed]
 
Bjoro K, Gjerstad L, Oystein B, et al: Topiramate and fulminant liver failure (letter). Lancet 352:1119, 1998
[PubMed]
 
Brandes JL: Practical use of topiramate for migraine prevention. Headache Suppl 1:S66–73, 2005
 
Bray GA, Hollander P, Klein S, et al: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 11:722–733, 2003
[PubMed]
 
Bussone G, Usai S, D'Amico D: Topiramate in migraine prophylaxis: data from a pooled analysis and open-label extension study. Neurol Sci 27 (suppl 2):159–163, 2006
 
Chengappa KN, Gershon S, Levine J: The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 3:215–232, 2001a
 
Chengappa [Roy Chengappa] KN, Levine J, Rathore D, et al: Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. European Psychiatry 16:186–190, 2001b
 
Chengappa [Roy Chengappa] KN, Schwarzman LK, Hulihan JF, et al: Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry 67:1698–1706, 2006
 
Chengappa [Roy Chengappa] KN, Kupfer DJ, Parepally H, et al: A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord 9:609–617, 2007
 
Citrome L: Antiepileptics in the treatment of schizophrenia, in Antiepileptic Drugs to Treat Psychiatric Disorders. Edited by McElroy SL, Keck PE Jr, Post RM. New York, Informa Healthcare, 2008, pp 187–206
 
Claudino AM, de Oliveira IR, Appolinario JC, et al: Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 68:1324–1332, 2007
[PubMed]
 
Damsa C, Warczyk S, Cailhol L, et al: Panic attacks associated with topiramate. J Clin Psychiatry 67:326–327, 2006
[PubMed]
 
DelBello MP, Findling RL, Kushner S, et al: A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 44:539–547, 2005
[PubMed]
 
Doan RJ, Clendenning M: Topiramate and hepatotoxicity (letter). Can J Psychiatry 45:937–938, 2000
[PubMed]
 
Doose DR, Streeter AJ: Topiramate: chemistry, biotransformation, and pharmacokinetics, in Antiepileptic Drugs, 5th Edition. Edited by Levy RH, Mattson RH, Meldrum BS, et al. Philadelphia, PA, Lippincott Williams & Wilkins, 2002, pp 727–734
 
Eliasson B, Gudbjörnsdottir S, Cederholm J, et al: Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes (Lond) 31:1140–1147, 2007
[PubMed]
 
Fraunfelder FW, Fraunfelder FT: Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 111:1275–1279, 2004
[PubMed]
 
Fraunfelder FW, Fraunfelder FT, Keates EU: Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology 111:109–111, 2004
[PubMed]
 
Gidal BE: Topiramate: drug interactions, in Antiepileptic Drugs, 5th Edition. Edited by Levy RH, Mattson RH, Meldrum BS, et al. Philadelphia, PA, Lippincott Williams & Wilkins, 2002, pp 735–739
 
Guille C, Sachs G: Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry 26:1035–1039, 2002
[PubMed]
 
Hedges DW, Reimherr FW, Hoopes SP, et al: Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 64:1449–1454, 2003
[PubMed]
 
Herrero AL, Del Olmo N, González-Escalada JR, et al: Two new actions of topiramate: inhibition of depolarizing GABAA-mediated responses and activation of a potassium conductance. Neuropharmacology 42:210–220, 2002
[PubMed]
 
Hoopes SP, Reimherr FW, Hedges DW, et al: Part I. Topiramate in the treatment of bulimia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64:1335–1341, 2003
[PubMed]
 
Huguelet P, Morand-Collomb S: Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacol Res 52:392–394, 2005
[PubMed]
 
Johnson BA, Ait-Daoud N, Bowden CL, et al: Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 361:1677–1685, 2003
[PubMed]
 
Johnson BA, Ait-Daoud N, Akhtar FZ, et al: Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med 165:1600–1605, 2005
[PubMed]
 
Johnson BA, Rosenthal N, Capece JA, et al: Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641–1651, 2007
[PubMed]
 
Kaminski RM, Banerjee M, Rogawski MA: Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 46:1097–1104, 2004
[PubMed]
 
Kampman KM, Pettinati H, Lynch KG, et al: A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 75:233–240, 2004
[PubMed]
 
Kawasaki H, Tancredi V, D'Arcangelo G, et al: Multiple actions of the novel anticonvulsant drug topiramate in the rat subiculum in vitro. Brain Res 807(1–2):125–134, 1998
[PubMed]
 
Klufas A, Thompson D: Topiramate-induced depression (letter). Am J Psychiatry 158:1736, 2001
[PubMed]
 
Ko YH, Joe SH, Jung IK, et al: Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 28:169–175, 2005
[PubMed]
 
Kudin AP, Debska-Vielhaber G, Vielhaber S, et al: The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 45:1478–1487, 2004
[PubMed]
 
Kushner SF, Khan A, Lane R, et al: Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 8:15–27, 2006
[PubMed]
 
Kuzniecky R, Hetherington H, Ho S, et al: Topiramate increases cerebral GABA in healthy humans. Neurology 51:627–629, 1998
[PubMed]
 
Langtry HD, Gillis JC, Davis R: Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 54:752–773, 1997
[PubMed]
 
Loew TH, Nickel MK, Muehlbacher M, et al: Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 26:61–66, 2006
[PubMed]
 
Martin R, Kuzniecky R, Ho S, et al: Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 52:321–327, 1999
[PubMed]
 
McDaniel WW, Spiegel DR, Sahota AK: Topiramate effect in catatonia: a case series. J Neuropsychiatry Clin Neurosci 18:234–238, 2006
[PubMed]
 
McElroy SL, Keck PE Jr: Topiramate, in American Psychiatric Publishing Textbook of Psychopharmacology, 3rd Edition. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Publishing, 2004, pp 627–636
 
McElroy SL, Suppes T, Keck PE Jr, et al: Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 47:1025–1033, 2000
[PubMed]
 
McElroy SL, Arnold LA, Shapira AN, et al: Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo controlled trial (erratum in: Am J Psychiatry 160:612, 2003). Am J Psychiatry 160:255–261, 2003
[PubMed]
 
McElroy SL, Frye MA, Altshuler LL, et al: A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord 9:426–434, 2007a
 
McElroy SL, Hudson JI, Capece JA, et al: Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 61:1039–1048, 2007b
 
McElroy SL, Guerdjikova A, Keck PE Jr, et al: Antiepileptic drugs in obesity, psychotropic-associated weight gain, and eating disorders, in Antiepileptic Drugs to Treat Psychiatric Disorders. Edited by McElroy SL, Keck PE Jr, Post RM. New York, Informa Healthcare, 2008, pp 283–309
 
McIntyre RS, Mancini DA, McCann S, et al: Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 4:207–213, 2002
[PubMed]
 
McIntyre RS, Riccardelli R, Binder C, et al: Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Can J Psychiatry 50:415–422, 2005
[PubMed]
 
Meador KJ, Loring DW, Hulihan JF, et al: Differential cognitive and behavioral effects of topiramate and valproate. Neurology 60:1483–1488, 2003
[PubMed]
 
Michopoulos I, Douzenis A, Christodoulou C, et al: Topiramate use in alprazolam addiction. World J Biol Psychiatry 7:265–267, 2006
[PubMed]
 
Mohammadi B, Krampfl K, Cetinkaya C, et al: Interaction of topiramate with glycine receptor channels. Pharmacol Res 51:587–592, 2005
[PubMed]
 
Mula M, Sander JW: Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 30:555–567, 2007
[PubMed]
 
Mula M, Pini S, Cassano GB: The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 27:263–272, 2007
[PubMed]
 
Nickel C, Lahmann C, Tritt K, et al: Topiramate in the treatment of depressive and anger symptoms in female depressive patient: a randomized, double-blind, placebo-controlled study. J Affect Disord 87:243–252, 2005a
 
Nickel C, Tritt K, Muehlbacher M, et al: Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord 38:295–300, 2005b
 
Nickel MK, Nickel C, Mitterlehner FO, et al: Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 65:1515–1519, 2004
[PubMed]
 
Nickel MK, Nickel C, Kaplan P, et al: Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 57:495–499, 2005a
 
Nickel MK, Nickel C, Muehlbacher M, et al: Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol 25:211–217, 2005b
 
Ondo WG, Jankovic J, Connor GS, et al: Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 66:672–677, 2006
[PubMed]
 
Pascual J, Láinez MJ, Dodick D, et al: Antiepileptic drugs for the treatment of chronic and episodic cluster headache: a review. Headache 47:81–89, 2007
[PubMed]
 
Petroff OA, Hyder F, Rothman DL, et al: Topiramate rapidly raises brain GABA in epilepsy patients. Epilepsia 42:543–548, 2001
[PubMed]
 
Raskin P, Donofrio PD, Rosenthal NR, et al: Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 63:865–873, 2004
[PubMed]
 
Reife R, Pledger G, Wu S-C: Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 41 (suppl 1):S66–S71, 2000
 
Rho JM, Sankar R: The pharmacologic basis of antiepileptic drug action. Epilepsia 40:1471–1483, 1999
[PubMed]
 
Rosenfeld WE: Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 19:1294–1308, 1997
[PubMed]
 
Rosenfeld WE, Doose DR, Walker SA, et al: Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 38:317–323, 1997a
 
Rosenfeld WE, Kanner A, Jacobson M, et al: Topiramate and concomitant weight loss (abstract). Epilepsia 38 (suppl 8):98, 1997b
 
Rosenstock J, Hollander P, Gadde KM, et al: A randomized, double-blind, placebo-controlled multicenter study to assess the efficacy and safety of topiramate controlled-release in the treatment of obese, type 2 diabetic patients. Diabetes Care 30:1480–1486, 2007
[PubMed]
 
Sachdeo RC, Karia RM: Topiramate: adverse effects, in Antiepileptic Drugs, 5th Edition. Edited by Levy RH, Mattson RH, Meldrum BS, et al. Philadelphia, PA, Lippincott Williams & Wilkins, 2002, pp 760–764
 
Schiffer WK, Gerasimov MR, Marsteller DA, et al: Topiramate selectively attenuates nicotine induced increases in monoamine release. Synapse 42:196–198, 2001
[PubMed]
 
Shank RP, Gardocki JF, Streeter AJ, et al: An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41 (suppl 1):S3–S9, 2000
 
Shapira NA, Goldsmith TD, McElroy SL: Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 61:368–372, 2000
[PubMed]
 
Shorvon SD: Safety of topiramate: adverse events and relationships to dosing. Epilepsia 37 (suppl 2):S18–S22, 1996
 
Simeone TA, Wilcox KS, White HS: Subunit selectivity of topiramate modulation of heteromeric GABA(A) receptors. Neuropharmacol 50:845–857, 2006
[PubMed]
 
Stenlöf K, Rössner S, Vercruysse F, et al: Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab 9:360–368, 2007
 
Thienel U, Neto W, Schwabe SK, et al: Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 110:221–231, 2004
[PubMed]
 
Tiihonen J, Halonen P, Wahlbeck K, et al: Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 66:1012–1015, 2005
[PubMed]
 
Tonstad S, Tykarski A, Weissgarten J, et al: Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 96:243–251, 2005
[PubMed]
 
Toplak H, Hamann A, Moore R, et al: Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obesity 31:138–146, 2007
[PubMed]
 
Tremblay A, Chaput J-P, Bérubé S, et al: The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol 63:123–134, 2007
[PubMed]
 
Tucker P, Trautman RP, Wyatt DB, et al: Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:201–206, 2007
[PubMed]
 
van Passel L, Arif H, Hirsch LJ: Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Rev Neurother 6:19–31, 2006
 
Vieta E, Torrent C, Garcia-Ribas G, et al: Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol 22:431–435, 2002
[PubMed]
 
Vieta E, Goikolea JM, Olivares JM, et al: 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. J Clin Psychiatry 64:834–839, 2003
[PubMed]
 
Vieta E, Sanchez-Moreno J, Goikolea JM, et al: Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol 24:374–378, 2004
[PubMed]
 
Wauguier A, Zhou S: Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 24:73–77, 1996
 
Welch BJ, Graybeal D, Moe OW, et al: Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis 48:555–563, 2006
[PubMed]
 
White HS: Topiramate: mechanisms of action, in Antiepileptic Drugs, 5th Edition. Edited by Levy RH, Mattson RH, Meldrum BS, et al. Philadelphia, PA, Lippincott Williams & Wilkins, 2002, pp 719–726
 
White HS: Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 45 (suppl 1):S48–S56, 2005
 
White HS, Brown SD, Woodhead JH, et al: Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41 (suppl 1):S17–S20, 2000
 
White HS, Smith MD, Wilcox KS: Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 81:85–110, 2007
[PubMed]
 
Wilding J, Gaal L, Rissanan A, et al: A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28:1399–1410, 2004
[PubMed]
 
Winkelman JW: Efficacy and tolerability of open-label topiramate in the treatment of sleep-related eating disorder: a retrospective case series. J Clin Psychiatry 67:1729–1734, 2006
[PubMed]
 
Winner P, Pearlman EM, Linder SL, et al: Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 45:1304–1312, 2005
[PubMed]
 
Zhang X, Velumian AA, Jones OT, et al: Modulation of high voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 41 (suppl 1):S52–S60, 2000
 
Zullino DF, Krenz S, Zimmerman G, et al: Topiramate in opiate withdrawal—comparison with clonidine and with carbamazepine/mianserin. Subst Abus 25:27–33, 2004
[PubMed]
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
Which of the following describes a pharmacological property of topiramate?
2.
Which of the following statements concerning topiramate’s pharmacokinetic profile is true?
3.
Data from randomized, placebo-controlled clinical trials suggest that topiramate is efficacious in the treatment of
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts, 3rd Edition > Chapter 56.  >
What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 43.  >
Topic Collections
Psychiatric News
PubMed Articles
Painful diabetic neuropathy: an update. Ann Neurosci 2011;18(4):168-175.doi:10.5214/ans.0972-7531.1118409.
An effective initial polytherapy for children with West syndrome. Neural Regen Res 2013;8(17):1623-30.doi:10.3969/j.issn.1673-5374.2013.17.011.
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation